Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib with KHAD in castration-resistant prostate cancer
NCT00953576Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2009
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lapatinib in prostate cancer (PCa), sponsored by Dana-Farber Cancer Institute. Started Sep 2009; status: terminated.
02
Drugs
lapatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00953576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00953576.